Next-Generation Bispecific Nanobody Targeting IL17RA and TNF for Advanced Psoriasis Therapy

VHH-P596 is an innovative humanized nanobody-based bispecific antibody construct designed to target both interleukin 17 receptor A (IL17RA) and tumor necrosis factor (TNF). Developed as a potential treatment for psoriasis, VHH-P596 is currently at the Biological Testing stage. Its dual-target approach aims to disrupt critical inflammatory pathways central to psoriasis pathogenesis. The fully humanized design bolsters clinical translation prospects, minimizing immunogenicity risks while optimizing therapeutic selectivity and efficacy. By simultaneously targeting IL17RA and TNF, VHH-P596 aims to address significant unmet needs in this chronic skin disease.

Licensing Opportunity

VHH-P596 is available for out-licensing and strategic collaboration opportunities to pharmaceutical partners seeking novel psoriasis treatments. We welcome discussions with parties interested in innovative nanobody-based therapeutics.

Development Phase

Modality

VHH-P596 employs a bispecific antibody fusion modality, featuring a humanized single-domain antibody (VHH) architecture. This construct comprises a nanobody specific for IL17RA combined with another nanobody targeting TNF, both fused through a human IgG1 Fc domain. The unique single-domain nanobody format provides exceptional tissue penetration and molecular stability, essential for targeting complex inflammatory microenvironments seen in psoriasis. The modular structure enhances manufacturability and flexibility, allowing for tailored immune modulation while potentially reducing dosing frequencies. These structural advantages are particularly relevant for treating chronic inflammatory diseases such as psoriasis, where deep and sustained tissue targeting is crucial.

Target

IL17RA and TNF are pivotal protein targets implicated in inflammatory diseases. IL17RA, a cell-surface receptor predominantly expressed on keratinocytes and immune cells, mediates pro-inflammatory signaling pathways central to psoriasis pathogenesis. TNF, a multifunctional cytokine found in immune cells and inflamed tissues, amplifies inflammatory responses and promotes keratinocyte proliferation. Both IL17RA and TNF are highly expressed in psoriatic lesions, making them validated intervention points in disease management. Targeting IL17RA and TNF with VHH-P596 offers a strategic advantage by simultaneously modulating two critical nodes in the inflammatory cascade. This bispecific approach holds potential for enhanced efficacy and broader disease control in psoriasis compared to single-target agents.

Mechanism of Action

VHH-P596 functions by dual engagement of IL17RA and TNF, acting as a signal transduction modulator. The anti-IL17RA component specifically binds to IL17RA, blocking IL-17-driven pro-inflammatory pathways associated with keratinocyte activation and immune cell recruitment. Concurrently, the anti-TNF domain neutralizes TNF-mediated cytokine signaling, further suppressing inflammatory cascades that exacerbate psoriatic symptoms. By inhibiting both IL17RA and TNF signaling, VHH-P596 aims to disrupt synergistic inflammatory mechanisms in psoriasis. Furthermore, the nanobody platform enables modular engineering, laying a foundation for future development into formats such as antibody-drug conjugates (ADC) or advanced multispecific antibodies.

Psoriasis

Psoriasis is a chronic, immune-mediated skin disorder characterized by erythematous plaques, scaling, and persistent inflammation, affecting millions globally. The disease involves a complex interplay between genetic predisposition, environmental triggers, and dysregulated immune signaling, with the IL-17 and TNF pathways playing a central role. Current treatment strategies range from topical therapies and systemic immunomodulators to biologics targeting singular molecules within the inflammatory cascade. While these options have significantly improved disease management, challenges remain, including incomplete clinical responses, long-term safety concerns, and loss of efficacy due to immunogenicity or disease heterogeneity. Unmet needs persist for therapies offering deeper, more sustained responses with optimal safety profiles. VHH-P596, by targeting both IL17RA and TNF, addresses the multifactorial nature of psoriasis and offers the potential for superior disease control, setting a new benchmark for next-generation psoriasis interventions.